FASTER
Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 100 patients (estimated)
- Sponsors
- Sarah Cannon Research Institute
- Collaborators
- Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT), Pfizer
- Tags
- Autologous Stem Cell Transplant, Bispecific Antibody, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2169
- NCT Identifier
- NCT06974786
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.